Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn’s and Colitis Organisation ...
July 06 2021 - 8:05AM
Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical
company pioneering differentiated therapies for patients with liver
and gastrointestinal diseases, today announced that it will present
new preclinical data at the European Crohn’s and Colitis
Organisation (ECCO) 2021 Virtual Congress on July 9, 2021.
“These data provide compelling evidence that FXR activation can
improve commonly dysregulated pathways in inflammatory bowel
disease (IBD),” said Hubert C. Chen, M.D., chief medical officer,
Metacrine. “FXR agonism reduces innate immunity cell types without
immunosuppression, potentially offering a unique treatment option
for people with IBD that can also be used in combination regimens.
We look forward to initiating a Phase 2a trial in IBD in the first
half of 2022.”
The Company’s poster is:
Title: Activation of FXR Restores Expression of
Genes Dysregulated in Human IBD and Suppresses TNFa and IL-6
Signaling Pathways in Adoptive Transfer Colitis Model
ePoster Number: P029
Presentation Date and Time: July 9, 2021,
8:30 a.m. CEST
About Metacrine
Metacrine, Inc. is a clinical-stage biopharmaceutical company
building a pipeline of differentiated therapies to treat liver and
gastrointestinal diseases. Metacrine has developed a proprietary
farnesoid X receptor (FXR) platform utilizing a unique chemical
scaffold, which has demonstrated an improved therapeutic profile in
clinical trials. The Company’s two product candidates,
MET409 and MET642, are currently being investigated in clinical
trials as potential new treatments for NASH. MET409 has
completed a 12-week monotherapy trial in patients with NASH and is
being evaluated in a 12-week combination trial with empagliflozin
in patients with both NASH and type 2 diabetes. MET642 has
completed a 14-day Phase 1 trial in healthy volunteers and is being
evaluated in a 16-week monotherapy trial in patients with NASH. To
learn more, visit www.metacrine.com.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements in
this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, statements about plans for initiating
future clinical trials and studies; and the potential for its FXR
product candidates to be therapies for IBD. Words such as “may,”
“will,” “expect,” “plan,” “aim,” “projected,” “likely,
”anticipate,” “estimate,” “intend,” “potential,” “prepare,”
“perceived,” “believes” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Metacrine’s
expectations and assumptions that may never materialize or prove to
be incorrect. Each of these forward-looking statements involves
risks and uncertainties. Actual results may differ materially from
those projected in any forward-looking statements due to numerous
risks and uncertainties, including but not limited to: the risk
that existing preclinical and clinical data may not be predictive
of the results of ongoing or later clinical trials; risks and
uncertainties regarding regulatory approvals for MET409 or MET642;
potential delays in initiating, enrolling or completing any
clinical trials; potential adverse side effects or other safety
risks associated with Metacrine’s product candidates; competition
from third parties that are developing products for similar uses;
and Metacrine’s ability to obtain, maintain and protect its
intellectual property Other factors that may cause actual results
to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Metacrine’s
filings with the U.S. Securities and Exchange Commission, including
the “Risk Factors” contained therein. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Except as required by law, Metacrine
assumes no obligation to update any forward-looking statements
contained herein to reflect any change in expectations, even as new
information becomes available.
Investor & Media Contact
Steve Kunszabo
Metacrine, Inc.
+1 (858) 369-7892
skunszabo@metacrine.com
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Apr 2023 to Apr 2024